ENTO
Entero TherapeuticsENTO
ENTO
About: Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Employees: 11
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 [Q2] → 10 (+2) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
2.51% less ownership
Funds ownership: 5.39% [Q2] → 2.87% (-2.51%) [Q3]
88% less capital invested
Capital invested by funds: $183K [Q2] → $21.1K (-$162K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for ENTO.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Entero Therapeutics, Inc. (NASDAQ: ENTO ), relating to the proposed merger with Journey Therapeutics, Inc. Under the terms of the agreement, the shareholders of Journey will acquire 99% of the equity of Entero.
Neutral
Accesswire
1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pulmatrix, Inc. (NASDAQ:PULM)'s merger with Cullgen Inc. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. If you are a Pulmatrix shareholder, click here to learn more about your rights and options.
Neutral
Business Wire
1 month ago
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Entero Therapeutics, Inc. (NasdaqCM: ENTO) and Journey Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. KSF is seeking to determine whether the merger and the process that led to it are adequ.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Entero Therapeutics, Inc. Merger
WILMINGTON, DE / ACCESSWIRE / November 14, 2024 / Rigrodsky Law, P.A. is investigating Entero Therapeutics, Inc. ("Entero") (NASDAQ:ENTO) regarding possible breaches of fiduciary duties and other violations of law related to Entero's agreement to merge with Journey Therapeutics, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-entero-therapeutics-inc.
Neutral
GlobeNewsWire
1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
Business Wire
1 month ago
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Entero (Nasdaq: ENTO) for possible breaches of fiduciary duty and other violations of law in its transaction with Journey. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, the shareholders of Journey will acquire 99% of the equity of Entero. The transaction agreement un.
Neutral
Business Wire
1 month ago
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQ: ENTO) and Journey Therapeutics, Inc. is fair to Entero shareholders. Upon closing of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. Halper Sadeh encourages Entero shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh.
Neutral
GlobeNewsWire
1 month ago
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
BOCA RATON, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), today announced that it has entered into a binding term sheet for a reverse merger transaction (the “Proposed Merger”) with Journey Therapeutics, Inc. (“Journey”), a privately-held, clinical-stage biopharmaceutical company with a next-generation proprietary modular antibody-drug conjugate (ADC)-like, nano-immunoconjugates (NIC) platform. Upon completion of the Proposed Merger, the shareholders of Journey will acquire 99% of the equity of Entero. The combined company is expected to operate under the name Journey Therapeutics, Inc., and will apply for continued trading on The Nasdaq Capital Market. The completion of the Proposed Merger is subject to several conditions, including the negotiation of definitive agreements, the receipt by Entero of at least $5 million of equity financing, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission and the approval of the stockholders of Entero.
Neutral
Business Wire
2 months ago
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nea.
Neutral
GlobeNewsWire
3 months ago
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company's plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.
Charts implemented using Lightweight Charts™